Platycodin-D Induced Autophagy in Non-Small Cell Lung Cancer Cells via PI3K/Akt/mTOR and MAPK Signaling Pathways.

Ruolin Zhao, Nanjing University
Meijuan Chen, Nanjing University
Zequn Jiang, Nanjing University
Fengming Zhao, Nanjing University
Beili Xi, Nanjing University
Xu Zhang, Nanjing University
Haian Fu, Emory University
Kunfu Zhou, Nanjing University

Journal Title: Journal of Cancer
Volume: Volume 6, Number 7
Publisher: Ivyspring International Publisher | 2015, Pages 623-631
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.7150/jca.11291
Permanent URL: https://pid.emory.edu/ark:/25593/pqqdz

Final published version: http://dx.doi.org/10.7150/jca.11291

Copyright information:
© 2015 Ivyspring International Publisher
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits distribution, public display, and publicly performance, making multiple copies, provided the original work is properly cited. This license requires credit be given to copyright holder and/or author, copyright and license notices be kept intact. This license prohibits exercising rights for commercial purposes.

Accessed March 15, 2019 4:03 AM EDT
Abstract

Platycodin-D (PD) is an effective triterpene saponin extracted from the root of Platycodon grandiflorum which has been used clinically to treat pulmonary diseases in traditional Chinese medicine. Recently, it has been reported that PD has anti-tumor effects in various cancer models through the induction of apoptosis. However, whether PD induces autophagy in both cell lines and its molecular mechanisms have not been elucidated. Here, our present study confirmed that PD induced autophagy in both NCI-H460 and A549 cells via up-regulating the expression levels of Atg-3, Atg-7 and Beclin-1. Meanwhile, PD contributed to the up-regulation of LC3-II at both protein and mRNA levels. Further detection of the PI3K/Akt/mTOR signaling pathway compared to LY294002 (PI3K kinase inhibitor), RAP (mTOR kinase inhibitor) and insulin (an activator of PI3K/Akt/mTOR signaling pathway) showed that PD induced autophagy through inhibiting the pathway at p-Akt (Ser473), p-p70S6K (Thr389) and p-4EBP1 (Thr37/46) in both cell lines. Moreover, the examination of MAPK signaling pathway showed that PD treatment increased the phosphorylation of JNK and p38 MAPK, while decreased the phosphorylation of Erk1/2 in both cell lines. Additionally, the effects assessed with a panel of pharmacologic inhibitors, including U0126 (Erk1/2 kinase inhibitor), SP600125 (JNK kinase inhibitor) and SB203580 (p38 MAPK kinase inhibitor) suggested that the activation of JNK and p38 MAPK participated in PD-induced autophagy. Taken together, these findings suggested that PD induced autophagy in NCI-H460 and A549 cells through inhibiting PI3K/Akt/mTOR signaling pathway and activating JNK and p38 MAPK signaling pathways. Therefore, PD may be an alternative compound for NSCLC therapy.

Key words: Platycodin-D, non-small cell lung cancer, autophagy, PI3K/Akt/mTOR, MAPK signaling pathways

Introduction

PD is a triterpenoid saponin isolated from the root of Platycodon grandiflorum, which has been widely used in traditional Chinese medicine for treatment against various pulmonary diseases and respiratory disorders [1-3]. Recently, it has been extensively investigated as a potential alternative ther-
apy for treatment of various cancers, including breast cancer, gastric cancer, leukemia, colon cancer and so on [1-3]. Our preliminary studies have demonstrated that PD has an anti-NSCLC effect associated with the induction of apoptosis, however, whether PD induces autophagy in NSCLC cells has yet to be identified.

Most anticancer drugs are associated with the induction of programmed cell death (PCD). Accumulating studies have suggested that autophagy (Type II PCD), consistent with apoptosis (Type I PCD), is also important for the regulation of cancer development and progression, and may be regarded as a potential therapeutic approach for anticancer researches [4]. However, recent evidence has indicated that apoptosis-induced agents may confer drug-resistance following the anticancer effects especially at the late stage of tumor development. Thus, autophagy which is an evolutionarily conserved catabolic process of self-degradation of organelles and cytosolic macromolecules has been considered as an alternative therapeutic approach in cancer cells [5]. Autophagy initiation which completed with the accumulation of the ULK1/2-ATG13-FIP200 complex results in development of the isolation membrane, also known as a phagosome. On receiving autophagic stimulus, the phagosome converts to autophagosome depending on autophagy-related genes (Atg) proteins, then its maturation is completed upon fusion with lysosome to form autophagolysosome [6].

Several signaling pathways have been demonstrated to interfere with autophagy. Among them, phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) and mitogen-activated protein kinase (MAPK) signaling pathways especially play a critical role in regulating establishment of autophagy in cancer cells [7-9]. Recent studies have demonstrated the constitutive activation of the PI3K/Akt/mTOR signaling pathway occurs in 90% of NSCLC cell lines, and the inhibition of this signaling cascade is not only important for induction of autophagic cell death but also for developing new treatments for NSCLC [10]. Consistent with the PI3K/Akt/mTOR signaling pathway, MAPK signaling pathways including extracellular signal-regulated kinase (Erk), p38 MAPK and c-jun NH2-terminal kinase (JNK) have been identified as chemotherapeutic targets for sensitizing cancer cells to autophagy [7, 8].

In this study, we aimed to investigate the effects of PD-induced autophagy in NCI-H460 and A549 cell lines and its underlying mechanisms focusing on the role of PI3K/Akt/mTOR and MAPK signaling pathways in PD-induced autophagy.

### Materials and methods

#### Reagents

Platycodin-D (PD) (MW: 1224.58, HPLC ≥ 98%) was purchased from Shanghai Yuanye biotechnology Co. Ltd. (Shanghai, China). The chemicals used were rapamycin, LY294002, U0126, SP600125 and SB203580 (Cell Signaling Technology, USA), insulin, Gimesa (Sigma, USA), TRizol reagent (Invitrogen, USA), Re-al-time PCR Master Mix (Toyobo, Japan). Mouse- or rabbit-polyclonal antibodies specific for LC3-I /II, Beclin-1, Atg-5 and Atg-7, p-Akt (Ser473), p-p70S6K (Thr389), p-4EBP1 (Thr37/46), Akt, p70S6K, 4EBP1, p-Erk1/2, p-JNK, p-JNK, p-p38 MAPK, β-actin and secondary antibodies (goat anti-mouse or anti-rabbit IgG-conjugated horseradish peroxidase (HRP)) were all purchased from Cell Signaling Technology (Beverly, USA).

#### Cell culture

Human NSCLC cells lines (A549 and NCI-H460) were obtained from the Institute of Biochemistry and Cell Biology (Shanghai, China). NCI-H460 and A549 cells were cultured in DMEM and F12 medium (HyClone, USA) respectively, supplemented with 10% fetal bovine serum (FBS) (Gibco, USA), 100 U/ml penicillin-streptomycin mixed antibiotics at 37°C in a humidified 5% CO2 incubator.

#### Transmission electron microscopy (TEM)

After being exposed to 20 or 30 µmol/L of PD for 24 h, the cells were trypsinized, washed with PBS and fixed in 2.5% glutaraldehyde in 0.1 mol/L phosphate buffer (pH 7.2) overnight at 4°C. The next day, cells were washed three times with 0.1 mol/L phosphate buffer. They were then fixed in 1% aqueous osmium, dehydrated with increasing concentrations of ethanol (30, 50, 70, 80, 90 and 100%), and embedded in araldite. Ultrathin sections were prepared with a microtome (Leica, Germany) and mounted on copper grids. The samples were stained with 2% aqueous uranyl acetate and lead citrate and observed in a transmission electron microscope (TEM; Jeol, Japan).

#### Western blot analysis

For western blot analysis, cells were lysed in RIPA buffer containing 50 mmol/L Tris/HCl (pH 8.0), 150 mmol/L NaCl, 1% Nonidet-P40, 1% sodium deoxycholate, 0.1% SDS, 0.1 mmol/L DTT, 0.05 mmol/L PMSF, 0.002 mg/ml aprotinin, 0.002 mg/ml leupeptin, and 1 mmol/L NaVO₃. The protein concentration of each supernatant was determined by the BCA protein assay. Equal amounts of protein were loaded and separated by 10 or 12% SDS-PAGE and then transferred onto polyvinylidene difluoride
membranes. The membranes were incubated overnight with appropriate primary antibodies against LC3-I/Ii, Beclin-1, Atg-5 and Atg-7, p-Akt (Ser473), p-p70S6K (Thr389), p-4EBP1 (Thr37/46), Akt, p70S6K, 4EBP1, p-Erk1/2, p-JNK, p-p38 MAPK or β-actin overnight at 4°C, and then with HRP-conjugated secondary antibodies (anti-rabbit or mouse immunoglobulin G) for an additional 1 h at room temperature. Immunoreactivity was detected by enhanced chemiluminescence (ECL) (Bio-Rad, USA). β-actin was used as a loading control. Quantitative analysis was performed by Image Lab™ software.

Quantitative reverse transcription-PCR for mRNA quantification

Total RNA was extracted using the TRIzol reagent (Invitrogen, USA), and cDNA was prepared using 0.5μg of oligo (dT) primers and the PrimeScript RT reagent (Toyobo, Japan) according to the manufacturer’s protocol. Quantitative reverse transcription-PCR (QRT-PCR) analysis was performed using SYBR green assays (TaKaRa) on the following genes using the following primers: LC3-II primer, Sense primer: 5’-AAACGCATTTGCCATCACAGT-3’ and Antisense primer: 5’-GTGAGGACTTTGGGTGTGGTC-3’; Human-GAPDH primer, Sense primer: 5’-

TGTTATCGTGGAGGACTCA-3’; Antisense primer: 5’-CCAGTAGAGCCAGGGATGAT-3’. Each test was carried out in triplicate according to standard protocol. Data were calculated using the 2^ΔΔCt method comparing ΔCt of treated A549 cells to ΔCt of control untreated samples. Reactions were incubated in the LightCycler 480 QRT-PCR system. Ct values were calculated using the SDS software version 2.3 applying automatic baseline and threshold settings.

Statistical analysis

All quantitative data presented were the mean ± SD from at least three independent experiments. The SPSS 19.0 software package was used to perform all statistical analysis. Comparisons between two groups were performed using the Student’s-t test and between multiple groups using ANOVA analysis. A value of P < 0.05 was considered statistically significant.

Results

Morphological changes of autophagy-induced by PD in NCI-H460 and A549 cells

NCI-H460 and A549 cells were treated with 0, 5, 10, 20 or 30 μmol/L of PD, respectively. After 24 h treatment, cells stained with Gimesa were observed using phase contrast microscopy. With the increasing concentrations of PD, cells had shrunk, accumulated vacuoles in the cytoplasm, and cell density significantly decreased compared with untreated control group (Fig. 1 A).

Figure 1. PD induced morphological changes of NCI-H460 and A549 cells. (A) NCI-H460 and A549 cells treated with PD at various concentrations of 0, 10, 20, and 30 μmol/L, respectively. After 24 h treatment, cells stained with Gimesa were observed using phase-contrast microscopy (+400). (B) NCI-H460 and A549 cells were exposed to 0, 20 and 30 μmol/L of PD for 24h followed by observation using a transmission electron microscope (TEM). Numerous autophagosomes with typical double-layer membranes containing organelle remnants were highlighted by arrows.
Transmission electron microscopy (TEM) is a conventional method for monitoring autophagy. Through TEM detection, we found cytoplasmic vacuoles in both NCI-H460 and A549 cells after exposure to 20 or 30 μmol/L of PD for 24 h, and the cytoplasmic vacuoles had double-layered membranes and many of them contained cytoplasmic organelles or myelin figures (Fig. 1 B). Particularly, with the increasing concentrations of PD treatment, the vacuoles increased in size and number and fused into larger vacuoles compared with the untreated control group (Fig. 1 B). These morphological changes indicated that PD induced autophagosome formation. Thus, we speculated the treatment with PD might induce autophagy in both cell lines.

**PD induced autophagy in NCI-H460 and A549 cells**

To confirm the exact effects of PD on induction of autophagy in NCI-H460 and A549 cells, autophagy-related genes proteins, which are called Atg proteins including LC3-I/II (Atg-8), Beclin-1 (Atg-6), Atg-3 and Atg-7 were detected by western blot analysis. Our data showed that with PD treatment, the expression of Beclin-1, Atg-3 and Atg-7 and the conversion of LC3-I to LC3-II increased in a dose- and time-dependent manner (Fig. 2 A-D). We next examined the expression of LC3-II, which serves as an ultimate biomarker of autophagy, at the mRNA level by using qRT-PCR. The data in Fig. 2 E demonstrated that the mRNA level of LC3-II was dramatically up-regulated after 20 or 30 μmol/L of PD treatment for 24 h (P < 0.01, P < 0.05, respectively). Collectively, these results provided evidence that PD induced autophagy in NCI-H460 and A549 cell lines.

![Figure 2. Effect of PD on inducing autophagy in NCI-H460 and A549 cells.](http://www.jcancer.org)
Effects of PD on PI3K/Akt/mTOR signaling pathway for induction of autophagy in NCI-H460 and A549 cells

The PI3K/Akt/mTOR signaling pathway plays a critical role in cell proliferation and autophagy. To better understand the molecular mechanisms of PD-induced autophagy, we determined the possible involvement of this signaling pathway. As shown in Fig. 3 A and B, the expression levels of p-Akt (Ser473), p-p70S6K (Thr389), and p-4EBP1 (Thr37/46) were significantly inhibited in both NCI-H460 and A549 cells after PD treatment alone (Fig. 3 A and B). Similarly, to LY294002, PD inhibited p-Akt (Ser473), p-p70S6K (Thr389), and p-4EBP1 (Thr37/46); however, this effect of insulin was reduced by PD treatment alone (Fig. 3 E, F and H).

We further investigated the effect of PD on the PI3K/Akt/mTOR/p70S6K/4EBP1 pathway compared with LY294002 (an inhibitor of PI3K) and RAP (an inhibitor of mTOR)[11, 12]. Similarly to LY294002, PD inhibited p-Akt (Ser473), meanwhile, it weakened the feedback activation of RAP on p-Akt (Ser473) in both cell lines (Fig. 3 C and D). Notably, the ratio of LC3-II/actin was enhanced by co-treatment with PD and LY294002 or PD and rapamycin compared with PD alone (P<0.05) (Fig. 3 C, D and G). Thus, PD had a synergistic effect on induction of autophagy with LY294002 or RAP.

Insulin not only activates PI3K/Akt/mTOR signaling pathway but also suppresses autophagy [13, 14]. As shown in Fig. 3 E and F, 30 min of insulin treatment significantly phosphorylated Akt (Ser473), p70S6K (Thr389), and 4EBP1 (Thr37/46). In contrast, when cells were pretreated with PD and then stimulated with insulin, the phosphorylation levels of them were significantly inhibited. Meanwhile, LC3-II/actin ratio in both cell lines was suppressed by insulin, however, this effect of insulin was reduced by PD pretreatment (P<0.01) (Fig. 3 E, F and H).

Taken together, it was clearly suggested that PD induced autophagy in NCI-H460 and A549 cells by inhibiting the PI3K/Akt/mTOR signaling pathway.

Effects of PD on MAPK signaling pathways for induction of autophagy in NCI-H460 and A549 cells

It has been suggested that MAPK signaling pathways are important for regulation of proliferation, differentiation, apoptosis, autophagy and cell cycle arrest [9, 11]. To investigate the role of MAPK signaling pathways in PD-induced autophagy, the activation of JNK, Erk1/2 and p38 MAPK was examined by Western blot assay using phosphorylated antibodies specific for the active forms of these kinases. The expression levels of p-p38 MAPK and p-JNK were activated by PD in a dose and time-dependent manner, however, p-Erk1/2 was inhibited by PD dose and time-dependently (Fig. 4 A and B).

To further clarify whether PD-induced autophagy depended on p-p38 MAPK and p-JNK activation and p-Erk1/2 suppression, cells were treated with U0126 (an inhibitor of Erk1/2), SP600125 (an inhibitor of JNK) or SB203580 (an inhibitor of p38) for 4 h followed by treatment with or without PD for 24h. Our date showed that the ratio of LC3-II/LC3-I was dramatically increased in PD co-treatment with SP600125 or SB203580 group compared with that in SP600125 or SB203580 treatment group (P<0.01) (Fig. 4 C-F), suggesting the activation of p-JNK or p-p38 MAPK was involved in cell autophagy. Though the ratio of LC3-II/LC3-I in U0126 treatment group was increased, the ratio of LC3-II/LC3-I in PD co-treatment with U0126 group was lower than that by PD treatment alone (Fig. 4 F), suggesting inhibition of p-Erk1/2 was not involved in cell autophagy.

Taken together, these results demonstrated that PD induced autophagy in NCI-H460 and A549 cells through activation of p-p38 MAPK and p-JNK, while inhibition of p-Erk1/2 was not responsible for PD-induced autophagy.

Discussion

Currently, it has been reported that PD effectively induces apoptosis in many cancer cells [1-3]. And our previous studies had found PD significantly inhibited cell proliferation and viability in NSCLC cell lines NCI-H460 and A549 in a dose- and time-dependent manner, and it induced apoptosis through mitochondrial-dependent and Erk signaling pathways (under submitting). However, whether PD induces autophagy and its molecular mechanisms remains unknown.

Autophagy is considered an alternative therapeutic approach in cancer cells [5, 15]. Autophagic processes start with the formation of autophagosome, which is enclosed within double-membrane that entrap cytoplasmic components. Then, autophagosome fuse with lysosome to generate autophaglysome, where cytoplasmic molecules and organelles are degraded by lysosomal hydrolyases (Fig. 5) [16]. Initially, we found that most of the cells exposed to PD for 24 h had shrunk, accumulated vacuoles in the cytoplasm, and cell density decreased compared with the untreated control in dose-dependent manner (Fig. 1 A). Cell morphology observed with TEM showed that cytoplasmic vacuoles had double-layered membranes and only some cytoplasmic organelles or myelin figures remained in both cell lines after 24 h treatment of PD (Fig. 1 B).
Figure 3. Effect of PD on PI3K/Akt/mTOR/p70S6k/4EBP1 signaling pathway in NCI-H460 and A549 cells. (A and B) NCI-H460 and A549 cells treated with 0, 5, 10, 20 and 30 µmol/L of PD for 24 h or 30 µmol/L of PD for 0, 3, 6, 12 and 24 h were analyzed by western-blot with antibodies against p-Akt (Ser473), p-p70S6K(Thr389), p-4EBP1 (Thr37/46), Akt, p70S6K and 4EBP1. (C and D) NCI-H460 and A549 cells treated with 30 µmol/L of PD, 10 µmol/L of LY294002 or 10 µmol/L of Rapamycin for 24 h were analyzed by western-blot with antibodies against p-Akt (Ser473), p-p70S6K (Thr389), p-4EBP1 (Thr37/46), and LC3-I/II. (E and F) Cells treated with 30 µmol/L of PD for 24 h followed by treatment with or without 200 nmol/L of insulin for 30 min were analyzed by western-blot for the expression levels of p-Akt (Ser473), p-p70S6K (Thr389) and LC3-I/II. (G and H) Densitometry analysis of LC3-II level relative to actin was performed in both two cell lines. ○, □: P<0.05; and ○○, □□: P<0.01 versus PD + RAP values; *, △: P<0.05; and **, △△: P<0.01 Insulin versus PD + Insulin values; **: P<0.01 PD versus control values. Representative results of three independent experiments are shown. β-actin was used as a loading control. Error bars, SD.
Figure 4. Effect of PD on MAPK signaling pathways in NCI-H460 and A549 cells. (A and B) NCI-H460 and A549 cells treated with 0, 5, 10, 20 and 30 µmol/L of PD for 24 h or 30 µmol/L of PD for 0, 3, 6, 12 and 24 h were analyzed by western blot with antibodies against p-Erk1/2, p-JNK and p-p38 MAPK. (C and D) NCI-H460 and A549 cells treated with 20 µmol/L of SB203580, 20 µmol/L of U0126 or 20 µmol/L of SP600125 for 4 h followed by treatment with or without 30 µmol/L of PD for 24 h were analyzed by western blot with antibodies against p-Erk 1/2, p-JNK, p-p38 MAPK and LC3-I/II. (E and F) Densitometry analysis of LC3-II levels relative to LC3-I in NCI-H460 and A549 cells was performed. Representative results of three independent experiments are shown. β-actin was used as a loading control. Error bars, SD; □□: P<0.01 and □□□: P<0.001: versus PD + SB203580 values; ○○: P<0.01 and ○○○: P<0.001 versus PD + U0126 values; ***: P<0.01 and ****: P<0.001 versus PD + SP600125 values.

Among the processes of autophagy, autophagosome-formation is regulated by Atg proteins which are essential to regulate chemotherapy-induced autophagy encoded by the autophagy-related genes [17]. There are two ubiquitin-like conjugation systems about Atg proteins. The first one results in covalent attachment of the ubiquitin-like protein Atg-12-Atg-5 (together with Atg-16) catalyzed by Atg-7 [18]. In another system, the LC3-I/II (Atg-8) gets activated by Atg-7 and then undergoes lipidation with phosphatidylethanolamine (PE) by Atg-3 [19]. Moreover, Beclin-1 (Atg-6), a part of a class III PI3K complex, is necessary to form pre-autophagosomal structures [20]. Followed by the effects of Atg proteins, the cytoplasmic targets for autophagy are encapsulated in the autophagosome [4]. Our results indicated that PD induced autophagy as evidence by increasing the conversion of LC3-I to LC3-II and the accumulation of Atg-3, Atg-7 and Beclin-1 in a dose- and time-dependent manner (Fig. 2 A and B). LC3-II, recruited to forming autophagosomes, is an ultimate biomarker of autophagy [19]. Our data suggested that PD up-regulated the expression of LC3-II in both protein and mRNA levels in both cell lines (Fig. 2 C-E). Collectively, these results provided obvious evidence that PD induced autophagy in NCI-H460 and A549 cells.

Accumulating researches have highlighted that the inhibition of Akt and its downstream target p70S6K contribute to the initiation of autophagy, and the expression level of p-p70S6K could be utilized as a marker for mTOR activity. And the direct down-
stream target of p70S6K is 4EBP1 [21, 22]. As shown in Fig. 3 A and B, PD significantly decreased the expression levels of p-Akt (Ser473), p-p70S6K (Thr389) and p-4EBP1 (Thr37/46) in NCI-H460 and A549 cells. Compared with LY294002, which inhibits autophagy by the inhibition of class III PI3K [10], and RAP, which inhibits mTOR but has a negative feedback on Akt [23], PD decreased the activation of rapamycin on p-Akt (Ser473). Furthermore, the ratio of LC3-II/actin was enhanced by PD co-treatment with LY294002 or RAP compared with that by PD, LY294002 or RAP treatment alone (P<0.05), indicating that PD had a synergistic effect on induction of autophagy with LY294002 or RAP (Fig. 3 C, D and G). Subsequently, we used insulin to further clarify the correlation between insulin-mediated activation of the PI3K/Akt/mTOR pathway and PD-induced autophagy. Our results provided evidence that insulin activated this signaling pathway leading to autophagy suppression, the effect of insulin was abolished by PD addition (Fig.3 E and F). These results suggested that PD-induced autophagy in NCI-H460 and A549 cells was associated with the inhibition of PI3K/Akt/mTOR signaling pathway. 

MAPK signaling pathways which consist of Erk, JNK and p38 MAPK signaling pathways are involved in many cellular processes including cell growth, proliferation, autophagy and apoptosis. The JNK, Erk1/2 and p38 MAPK, which are activated by phosphorylation, are key regulatory proteins in these pathways. We observed that the expression levels of p-p38 MAPK and p-JNK were activated by PD in a dose and time-dependent manner, while the expression level of p-Erk1/2 was inhibited by PD (Fig. 4 A and B). To further clarify whether PD-induced autophagy was connected with p-p38 MAPK and p-JNK activation and p-Erk1/2 suppression, cells were pretreated with the pharmacological inhibitors SB203580, SP600125 or U0126 respectively, and then treated with or without PD. Notably, we found the conversion of LC3 I to LC3-II in PD co-treatment with SP600125 or SB203580 group was dramatically increased compared with that in SP600125 or SB203580 treatment group (P<0.01) (Fig. 4 C-F). Activation of the targeting JNK and p38 MAPK has been identified as chemotherapeutic agents for sensitizing cancer cells to autophagy [7, 24, 25]. In accordance with these findings, our results demonstrated the activation of JNK and p38 MAPK was involved in PD-induced autophagy in NCI-H460 and A549 cells. However, we also found the ratio of LC3-II/LC3-I in PD co-treatment with U0126 group was lower than that treated by PD alone, indicating that p-Erk1/2 was not responsible for PD-mediated autophagy (Fig. 4 F). And our previous study discovered that the inhibition of Erk signaling pathway by PD treatment induced apoptosis in NCI-H460 and A549 cells. Coordinate, increasing reports elucidate that among MAPK families Erk pathway is closely related with apoptosis [26, 27].

Figure 5. A schematic model of the molecular mechanisms associated with PD-induced autophagy in NCI-H460 and A549 cells. According to this model, when NCI-H460 and A549 cells were exposed to PD, the phagosome converted to double-layered membranes of autophagosomes through increasing expression levels of Atg proteins including Beclin-1, Atg-3 and Atg-7 as well as leading to the conversion of LC3-I to LC3-II. The inhibition of PI3K/Akt/mTOR signaling pathway and activation of JNK and p38 MAPK signaling pathways contributed to the accumulation of LC3-II, which were the possible upstream signaling pathways of PD-induced autophagy. Once the autophagosome was developed, its maturation was complete upon fusion with lysosome to form autophagolysosome. Eventually, programmed cell death was induced by PD. The schematic model compiled with the results and conclusions of this study (→: Stimulatory Modification, ⊥: Inhibitory Modification).
In conclusion, our experiments provided the first evidence that PD induced autophagy via inhibiting the PI3K/Akt/mTOR signaling pathway and activating JNK and p38 MAPK signaling pathways in NSCLC cells. Therefore, we speculated that PD may be an alternative therapeutic agent in the treatment of NSCLC. However, the intricate relationship between autophagy and apoptosis poses a big challenge for cancer treatment, as well as the cross-talk between PI3K/Akt/mTOR and MAPK signaling associated with the function of autophagy is uncertain. Hence, further studies are required to investigate above relationships by PD treatment and anti-NSCLC effects of PD in vivo.

Acknowledgments

This study was supported by a project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), grants from the People Programme (Marie Curie Actions) of the European Union’s Seventh Framework Programme FP7/2007-2013/ under REA grant agreement n° PIR SES-GA-2013-612589, the U.S. National Institutes of Health grants P01 CA116676 and the Natural Science Foundation of Jiangsu Province (BK20131415).

Conflict of Interest

The authors have declared that no conflict of interest exists.

References